Q-omics provides the consensus-scored TMEM87B profile across patient tissues and cancer cell-line models. TMEM87B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM87B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TMEM87B RNA expression shows 20,733 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where TMEM87B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM87B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM87B survival associations across molecular data types. TMEM87B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM87B RNA expression–survival associations across cancer types. High TMEM87B expression shows unfavorable associations in KIRP, UVM, LIHC, LGG and HNSC, but favorable associations in BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM87B RNA expression.
This table summarizes TMEM87B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM87B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM87B shows higher tumor expression in HNSC, LUAD, STAD, BLCA, KIRP and LIHC. The HNSC box plot shows higher TMEM87B RNA expression in tumor versus normal tissue (log2 FC = +1.422, t-test p < 0.001).
This table shows molecular features associated with TMEM87B in patient tissues and cancer cell lines. In patient samples, TMEM87B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM87B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
